Literature DB >> 29723040

Role of the blood coagulation cascade in hepatic fibrosis.

Asmita Pant1,2, Anna K Kopec1,2, James P Luyendyk1,2,3.   

Abstract

Liver is the primary source of numerous proteins that are critical for normal function of the blood coagulation cascade. Because of this, diseases of the liver, particularly when affiliated with severe complications like cirrhosis, are associated with abnormalities of blood clotting. Although conventional interpretation has inferred cirrhosis as a disorder of uniform bleeding risk, it is now increasingly appreciated as a disease wherein the coagulation cascade is precariously rebalanced. Moreover, prothrombotic risk factors are also associated with a more rapid progression of fibrosis in humans, suggesting that coagulation proteases participate in disease pathogenesis. Indeed, strong evidence drawn from experimental animal studies indicates that components of the coagulation cascade, particularly coagulation factor Xa and thrombin, drive profibrogenic events, leading to hepatic fibrosis. Here, we concisely review the evidence supporting a pathologic role for coagulation in the development of liver fibrosis and the potential mechanisms involved. Further, we highlight how studies in experimental animals may shed light on emerging clinical evidence, suggesting that beneficial effects of anticoagulation could extend beyond preventing thrombotic complications to include reducing pathologies like fibrosis.

Entities:  

Keywords:  anticoagulants; coagulation; fibrosis; liver

Mesh:

Substances:

Year:  2018        PMID: 29723040      PMCID: PMC6139645          DOI: 10.1152/ajpgi.00402.2017

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  79 in total

Review 1.  Haemostatic abnormalities in patients with liver disease.

Authors:  Ton Lisman; Frank W G Leebeek; Philip G de Groot
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

2.  The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis.

Authors:  Bradley P Sullivan; Paul H Weinreb; Shelia M Violette; James P Luyendyk
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

3.  The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells.

Authors:  Marina Vilaseca; Héctor García-Calderó; Erica Lafoz; Oihane García-Irigoyen; Matías A Avila; Joan Carles Reverter; Jaume Bosch; Virginia Hernández-Gea; Jordi Gracia-Sancho; Joan Carles García-Pagán
Journal:  Hepatology       Date:  2017-05-02       Impact factor: 17.425

Review 4.  Hypercoagulability in cirrhosis: causes and consequences.

Authors:  A Tripodi; Q M Anstee; K K Sogaard; M Primignani; D C Valla
Journal:  J Thromb Haemost       Date:  2011-09       Impact factor: 5.824

Review 5.  Coagulation abnormalities in the cirrhotic patient.

Authors:  Jimena Muciño-Bermejo; Raúl Carrillo-Esper; Misael Uribe; Nahum Méndez-Sánchez
Journal:  Ann Hepatol       Date:  2013 Sep-Oct       Impact factor: 2.400

6.  Fibrinogen deficiency increases liver injury and early growth response-1 (Egr-1) expression in a model of chronic xenobiotic-induced cholestasis.

Authors:  James P Luyendyk; Karen M Kassel; Katryn Allen; Grace L Guo; Guodong Li; Glenn H Cantor; Bryan L Copple
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 7.  Tissue-specific hemostasis in mice.

Authors:  Nigel Mackman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-08-25       Impact factor: 8.311

8.  Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat.

Authors:  Wataru Abe; Kenichi Ikejima; Tie Lang; Kyoko Okumura; Nobuyuki Enomoto; Tsuneo Kitamura; Yoshiyuki Takei; Nobuhiro Sato
Journal:  J Hepatol       Date:  2006-10-25       Impact factor: 25.083

Review 9.  Platelets as Modulators of Liver Diseases.

Authors:  Ton Lisman; James P Luyendyk
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

10.  Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages.

Authors:  Yiannis N Kallis; Christopher J Scotton; Alison C Mackinnon; Robert D Goldin; Nicholas A Wright; John P Iredale; Rachel C Chambers; Stuart J Forbes
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more
  14 in total

1.  Endothelial force awakens a mechanism of portal hypertension: It's a neutrophil extracellular trap!

Authors:  Dafna J Groeneveld; James P Luyendyk
Journal:  J Thromb Haemost       Date:  2019-06-28       Impact factor: 5.824

Review 2.  Mesenchymal Stem/Stromal Cells in Progressive Fibrogenic Involvement and Anti-Fibrosis Therapeutic Properties.

Authors:  Chenghai Li; Bin Wang
Journal:  Front Cell Dev Biol       Date:  2022-06-01

Review 3.  Anticoagulation in Cirrhosis: Evidence for the Treatment of Portal Vein Thrombosis and Applications for Prophylactic Therapy.

Authors:  Kylee Martens; Hannah S McMurry; Steven Koprowski; Justine Hum; Jessica Haraga; Janice H Jou; Joseph J Shatzel
Journal:  J Clin Gastroenterol       Date:  2022-04-29       Impact factor: 3.174

4.  Generation of neutrophil extracellular traps in patients with acute liver failure is associated with poor outcome.

Authors:  Fien A von Meijenfeldt; R Todd Stravitz; Jingwen Zhang; Jelle Adelmeijer; Yoh Zen; Valerie Durkalski; William M Lee; Ton Lisman
Journal:  Hepatology       Date:  2021-12-12       Impact factor: 17.298

5.  Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.

Authors:  Vidya Perera; Grigor Abelian; Danshi Li; Zhaoqing Wang; Liping Zhang; Susan Lubin; Wei Chen; Akintunde Bello; Bindu Murthy
Journal:  Clin Pharmacokinet       Date:  2022-03-09       Impact factor: 5.577

6.  GPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1.

Authors:  Katarina Zmajkovicova; Yasmina Bauer; Katalin Menyhart; Marie Schnoebelen; Diego Freti; Maxime Boucher; Bérengère Renault; Rolf Studer; Magdalena Birker-Robaczewska; Axel Klenk; Oliver Nayler; John Gatfield
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

Review 7.  The hemostatic and thrombotic complications of liver disease.

Authors:  Hannah Stowe McMurry; Janice Jou; Joseph Shatzel
Journal:  Eur J Haematol       Date:  2021-07-29       Impact factor: 2.997

Review 8.  Finding Solutions for Fibrosis: Understanding the Innate Mechanisms Used by Super-Regenerator Vertebrates to Combat Scarring.

Authors:  Fallon Durant; Jessica L Whited
Journal:  Adv Sci (Weinh)       Date:  2021-05-24       Impact factor: 16.806

9.  Liver fibrosis is driven by protease-activated receptor-1 expressed by hepatic stellate cells in experimental chronic liver injury.

Authors:  Lauren G Poole; Asmita Pant; Holly M Cline-Fedewa; Kurt J Williams; Bryan L Copple; Joseph S Palumbo; James P Luyendyk
Journal:  Res Pract Thromb Haemost       Date:  2020-06-25

10.  Coagulation parameters are associated with the prognosis of immunoglobulin a nephropathy: a retrospective study.

Authors:  Ming Xia; Di Liu; Liang Peng; Yan Li; Haiyang Liu; Lingzhi Wu; Guochun Chen; Yu Liu; Hong Liu
Journal:  BMC Nephrol       Date:  2020-10-27       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.